PMID: 11925292Apr 2, 2002Paper

A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia

The American Journal of Psychiatry
John M KaneRobert Conley

Abstract

Maintenance medication is critical in the prevention of psychotic relapse and rehospitalization among patients with schizophrenia. Given potential adverse effects, identification of the minimum effective dose is clinically important. A multicenter, double-blind study was conducted to determine rates of symptomatic exacerbation and adverse effects in 105 outpatients with schizophrenia randomly assigned to four different fixed doses of haloperidol decanoate and treated for 1 year or until relapse. The doses used were 25, 50, 100, and 200 mg given intramuscularly once per month. Rates of symptomatic exacerbation were 15% in the 200-mg group, 23% with 100 mg, 25% with 50 mg, and 60% with 25 mg. No significant differences in outcome were found between the groups treated with 200, 100, and 50 mg. Among the patients who completed the trial with no symptomatic exacerbation, there were no differences between dose groups on measures of psychopathology at the final rating point. The results of this study suggest that the 200-mg/month dose of haloperidol decanoate is associated with the lowest rate of symptomatic exacerbation (15%) with minimal increased risk of adverse effects or subjective discomfort in comparison to 100 or 50 mg. At the...Continue Reading

Citations

Nov 4, 2006·Der Nervenarzt·W W Fleischhacker, W Hummer
May 24, 2005·Schizophrenia Research·Robert A LasserJohn M Kane
Oct 31, 2003·The New England Journal of Medicine·Robert Freedman
May 2, 2007·Schizophrenia Bulletin·Mark OlfsonHaya Ascher-Svanum
Dec 4, 2009·Schizophrenia Bulletin·Robert W BuchananUNKNOWN Schizophrenia Patient Outcomes Research Team (PORT)
Jun 23, 2004·Journal of Clinical Psychopharmacology·John M Davis, Nancy Chen
Jun 18, 2004·International Clinical Psychopharmacology·Martin TurnerMariëlle Eerdekens
Jun 30, 2004·CNS Drugs·Bruce J KinonPeter F Buckley
May 28, 2010·The British Journal of Psychiatry. Supplement·David Taylor
Jul 31, 2009·European Psychiatry : the Journal of the Association of European Psychiatrists·G MarcheseL Pani
Dec 12, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN WFSBP Task force on Treatment Guidelines for Schizophrenia
May 31, 2014·Biochemical and Biophysical Research Communications·Weiqiang ChenKangsheng Li
Jan 7, 2011·The International Journal of Neuropsychopharmacology·Stefan LeuchtJohn M Davis
Feb 5, 2011·Journal of Psychopharmacology·Thomas R E Barnes, UNKNOWN Schizophrenia Consensus Group of British Association for Psychopharmacology
Jun 23, 2011·Journal of Clinical Psychopharmacology·Hiroyuki UchidaDavid C Mamo
Nov 24, 2006·Journal of Psychiatric Practice·Rajiv TandonUNKNOWN Treatment Effectiveness in Schizophrenia Consortium
Sep 3, 2017·The British Journal of Psychiatry : the Journal of Mental Science·Stefan Leucht, John M Davis
Jul 16, 2011·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Emmanuel StipMarc-André Roy
Nov 4, 2009·The Medical Journal of Australia·Simon B Dimmitt, Hans G Stampfer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.